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Abstract
Background: The prevalence of cancer increases every year, leading to a growing population of patients and
survivors in need for care. To achieve good quality care, a patient-centered approach is essential. Correct and timely
detection of needs throughout the different stages of the care trajectory is crucial and can be supported by the use
of screening and assessment in a stepped-care approach. The Cancer Rehabilitation Evaluation System (CARES) is a
valuable and comprehensive quality of life and needs assessment instrument. For use in Flemish research and
clinical practice, the CARES tool was translated for the Dutch-speaking part of Belgium (Flanders) from its original
English format. This protocol paper describes the translation and revalidation of this Flemish CARES version.
Methods: After forward-backward translation of the CARES into Flemish we aim to recruit 150 adult cancer patients
with a primary cancer diagnosis (stage I, II or III) for validation. In this study with a combination of qualitative and a
quantitative approach, qualitative data will be collected through focus groups and supplemented by two phases of
quantitative data collection: i) an initial patient survey containing questions on socio-demographic and medical
data, the CARES and seven concurrent instruments; and ii) a second survey administered after 1 week containing
the CARES and supplementary questions to explore their impressions on the content and the feasibility of the
CARES.
Discussion: With this extensive data collection process, psychometric validity of the Flemish CARES can be tested
thoroughly using classical test theory. Internal consistency of summary scales, test-retest reliability, content validity,
construct validity, concurrent validity and feasibility of the instrument will be examined. If the Flemish CARES
version is found reliable, valid and feasible, it will be used in future research and clinical practice. Comprehensive
assessment with the CARES in a stepped-care approach can facilitate timely identification of cancer patients’
psychosocial concerns and care needs so it can contribute to efficient provision of patient-centered quality care.
Trial registration: ClinicalTrials.gov: NCT02282696 (July 16, 2014).
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Background
The diagnosis of cancer has an enormous impact on
people’s lives. In additional to the threat on one’s phys-
ical health, cancer patients are confronted with psycho-
social problems and care needs [1–13]. Timely and
accurate detection of those psychosocial problems and
care needs is of great importance to offer more patient-
centered care, efficient referral and to prevent comorbid
psychopathology [14–18].Simple quality of life (QOL)
measurement and distress-screening are popular
methods to explore people’s psychosocial well-being [9,
19–22]. In contrast, needs assessment is a strategy that
focuses on identifying the unresolved concerns that pa-
tients are experiencing and determines if they desire fur-
ther assistance throughout the continuum of care [23].
Indeed, not all patients experiencing distress or reduced
QOL and need professional support from the care sys-
tem [24]. Needs assessment can provide important input
from the patients’ perspective and guide appropriate
intervention in the multidisciplinary process of care. As
a result of patient-report data, health care resources can
be allocated in the most appropriate way. The use of
needs assessment can therefore contribute to patient-
centered quality cancer care [14, 25–27].
To our knowledge there are no validated Flemish
needs assessment tools available. Therefore, this study
will be dedicated to the validation of a needs assessment
tool for use in Belgian research and clinical practice. To
provide a good understanding of psychosocial healthcare
needs, the content of a needs assessment tool should be
comprehensive enough to benefit multidisciplinary
stakeholders involved in cancer care i.e. medical special-
ists, nursing, psychologists, social welfare workers, gen-
eral practitioners, health insurance agencies. In the
search for an appropriate needs assessment tool, the fol-
lowing criteria were used: 1) the instrument should be
generic across tumor type and staging, i.e. suitable in all
cancer patients; 2) the assessment should encompass the
bio-psychosocial impact of the disease and treatment on
patients’ overall well-being i.e. physical, emotional, cog-
nitive, social, relational, sexual and financial, their daily
functioning and the potential resulting care needs; and,
3) the tool should have a proven psychometric robust-
ness, demonstrating good reliability and validity, and be
feasible for patients.
Several review studies describing needs assessment
tools for adult cancer patients are available [28–30].
From the tools discussed 24 instruments are patient-
reported outcomes (PRO) for adult patients with any
type of cancer. These needs assessment tools and associ-
ated psychometric properties are presented in brief in
Table 1 (and in full in Additional file 1).
Among other tools, the Cancer Rehabilitation Evalu-
ation System (CARES) was positively evaluated [28–30].
The CARES is a QOL and needs assessment instrument,
developed to provide an efficient way of gathering spe-
cific information about the day-to-day problems and re-
habilitation needs of cancer patients. The instrument
can be used for research or clinical objectives and has
been applied across cancer type and stage [31–44]. The
139 items of the CARES are placed under 31 subscales
and represented according to six summary scales, as
shown in Table 2. A copy of the original CARES ques-
tionnaire and patient score profile can be found in Add-
itional files 2 and 3.
The psychometric robustness of the CARES and its
earlier development versions (the Cancer Inventory
of Problem Situations) are well documented [33, 34,
36, 45]. The results demonstrate that the CARES
and its summary scales have excellent internal
consistency (α = 0.87–0.94) and high test-retest cor-
relations (r = 0.84–0.95). The instrument has moder-
ate to high correlations with the Symptom Checklist-
90 (SCL-90) [46], Dyadic Adjustment Scale (DAS)
[47], Karnofsky Performance status Scale (KPS) [48,
49] and a visual analogue scale [50] for QOL before
and after cancer, that were used to investigate con-
current validity. The content validity was supported
with the results from post-administration interviews
[35, 45].
Considering the CARES is reported as a valid and feas-
ible tool that can be used for all cancer patients to assess
a comprehensive range of bio-psychosocial aspects of
well-being, this instrument was chosen to be translated
and validated for further use in Flemish cancer care fa-
cilities and research.
The psychometric robustness of the Flemish CARES
version will be tested thoroughly. We plan to evaluate
the internal consistency of the CARES and its sum-
mary scales, the test-retest reliability will be consid-
ered, the construct validity will be explored, and the
concurrent validity of the CARES and its summary
scales will be checked with several comparative in-
struments. This paper describes the study protocol of
this multi-stepped process.
Methods
Translation of the CARES
Belgium is a trilingual country with Dutch, French and
German as official state languages. The Dutch language
in Belgium, called Flemish, is slightly different from the
Dutch language in the Netherlands in terms of vocabu-
lary. Since current CARES translation is made for the
Dutch-speaking part of Belgium, this paper refers to the
Flemish CARES version only. We have no knowledge of
a CARES translation appropriate for The Netherlands.
However, there is a translation of the CARES-Short
Form (CARES-SF) [51]. If one would like to use the full
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version of the CARES in The Netherlands, a revision of
the translation would be needed.
The Flemish CARES version resulted from a forward-
backward translation process with sworn translators and
an expert group, following the guidelines for translating
questionnaires described by Beaton et al. [52]. First,
sworn translators translated the original US English
CARES into Flemish. Two independent researchers re-
vised the resulting texts for content fidelity and an ex-
pert group, comprised of professionals from the field of
care management, oncology, primary care and psych-
ology, agreed on the final Flemish version. The question-
naire was again translated back into English by sworn
translators and the original CARES and English back-
translation were compared by a native speaker, conclud-
ing the content of the questionnaire was maintained.
Design of the study
A mix of qualitative and quantitative methods will be
used for the validation study of the Flemish CARES.
Qualitative data collection, that will be used to evalu-
ate content validity and feasibility of the instrument, will
consist of conducting focus group discussions until data
saturation is reached. We estimate that it will be neces-
sary to arrange four or five focus group discussions with
six to ten participants. The discussions will be facilitated
with several key questions and transcribed afterwards for
thematic content analysis. Further detailed description of
Table 1 Summary of needs assessment tools and psychometric properties
Instrument Validity Reliability Responsiveness Feasibility
Content Validity Other types of validity Internal consistency Reproducibility Time, Reading
Level,
Acceptability
CaNDI + + + + - T: - RL: + A: -
CARES + + + + - T: + RL: - A: +
CARES-SF + + + + + T: + RL: - A: -
CCM + + + + - T: + RL: + A: +
CHOICEs + - + - - T: + RL: - A: +
Concerns checklist + + - - - T: - RL: - A: -
CNAT + + + - - T: - RL: - A: +
CNQ-SF + + + - - T: + RL: + A: +
CPILS + + + - - T: - RL: - A: -
CPNS + - + - - T: + RL: - A: +
CPNQ + + + + - T: + RL: + A: -
Distressmanagement tool + - - - - T: - RL: - A: -
INM + - + - - T: - RL: - A: -
NEQ + + + + - T: - RL: - A: +
OCPC + - - - - T: - RL: - A: +
PINQ + + + - + T: - RL: - A: +
PNAS + - + - - T: - RL: - A: -
PNAT + + + + - T: + RL: - A: -
PNI + + + - - T: - RL: + A: -
Problem checklist + + + - - T: - RL: - A: +
SCNS + - + - - T: + RL: + A: +
SCNS-SF34 + + + - - T: - RL: + A: -
SNST + - - - - T: - RL: + A: +
Symptoms and concerns checklist + + + + - T: + RL: + A: +
+ : evidence for psychometric property
- : no evidence for psychometric property or evidence not available
Abbreviations: CaNDI (Cancer Needs Distress Inventory), CARES (Cancer Rehabilitation Evaluation System), CARES-SF (Cancer Rehabilitation Evaluation System-Short
Form), CCM (Cancer care monitor), CHOICEs assessment (Creating better health outcomes by improving communication about patients’ experiences assessment),
CNAT (Comprehensive needs assessment tool in cancer), CNQ-SF (Cancer Needs Questionnaire Short Form), CPILS (Cancer Problems in Living Scale), CPNS (Cancer
Patient Need Survey) CPNQ (Cancer Patient Need Questionnaire), Distress management tool, INM (Information Needs Measure), NEQ (Need Evaluation
Questionnaire), OCPC (Oncology Clinic Patient Checklist), PINQ (Patient Information Need Questionnaire), PNAS (Psychosocial needs assessment
survey), PNAT (Patient Needs Assessment Tool), PNI (Psychosocial Needs Inventory), Problem checklist, SCNS (Supportive Care Needs Survey),
SCNS-SF34 (Supportive Care Needs Survey Short Form), SNST (Supportive Care Needs screening Tool), Symptoms and concerns checklist
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this qualitative research activities will be part of another
publication, since we prefer to focus on a detailed de-
scription of the quantitative research in this paper.
For the quantitative data collection, questionnaires
containing the CARES and different complementary in-
struments (see further) will be used to evaluate reliabil-
ity, construct validity and concurrent validity. This
quantitative part of the validation study is described in
further detail in this protocol.
Sample size
There are no general criteria for the sample size in a
validation study, but a sample size of at least 50–100
is generally recommended [53]. Sample sizes in the
validation research of the original CARES varied for
each psychometric quality (Table 3) [35]. Two large
sample sizes of 479 and 1047 were used for the in-
vestigation of construct validity. Other aspects of re-
liability and validity were tested with sample sizes of
22 to 120 participants. Given the available time and
resources, setting the goal to include 150 partici-
pants for this validation study of the Flemish CARES
version is feasible. Considering the response rates of
40–60 % that are usually reached in the research do-
main of psycho-oncology, inviting at least 250 eli-
gible patients is a conservative approach to
guarantee the minimal amount of 150 participants.
Study population and recruitment
The CARES was constructed to detect rehabilitation
needs and QOL, with a secondary intent to stimulate pa-
tients’ competences and patient empowerment for in-
creased involvement in their own rehabilitation.
Therefore, only patients with a primary cancer diagnosis
treated with a curative intent will be recruited for this
validation study. Details on the in- and exclusion criteria
are listed in Table 4.
Participants will be recruited from four Flemish
hospitals (two public and two private, with a range
from 340 to 1015 beds). In order to generate a repre-
sentative research sample, several medical depart-
ments will conduct patient recruitment and include
medical oncology, radiotherapy, gynecology, urology,
and gastroenterology services.
Table 3 Sample sizes validation research original CARES
Psychometric quality Analysis Sample size
(N)
Test-retest reliability Correlations between CARES summary scores 71120
Rating agreement 71120
Construct validity Factor analysis on all items 479
Second-order factor analysis on 31 subscales 4791047
Concurrent validity Correlation between CARES and SCL-90 87
Correlation between CARES and SCL-90, DAS, KPS and QOL visual analogue scale 120
Sensitivity CARES compared to clinical interview 22
CARES compared to a needs assessment interview 2464
Content validityAcceptability to
patients
Questions on relevance of CARES content, completion time, understandability and
acceptability items.
2264
Abbreviations CARES Cancer Rehabilitation Evaluation System, SCL-90 Symptom Checklist-90, DAS Dyadic Adjustment Scale, KPS Karnofsky Performance status Scale




Physical (26) AmbulationActivities of daily livingRecreational activitiesWeight lossDifficulty workingPainClothing
Medical
Interaction (11)
Problems obtaining info from medical teamDifficulty communicating with medical teamControl of medical team
Maritala (18) Communication with partnerAffection with partnerInteraction with partnerOverprotection by partnerNeglect of care by
partner
Psychosocial (44) Body imagePsychological distressCognitive problemsDifficulty communicating with friends/relativesFriends/relatives
difficulty interactingAnxiety in medical situationsWorryInteraction with childrenaAt work concernsa
Sexual (8) Sex interestSexual dysfunctiona
Miscellaneous (32) ComplianceEconomic barriersDatingaChemotherapy-related problemsaRadiation-related
problemsaOstomyaProsthesisaMiscellaneous items
a Items may not apply to all patients
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Study procedure
Eligible patients will be selected by the medical team ac-
cording to the inclusion and exclusion criteria. Given
the complexity of the clinical field and variable struc-
tures of the participating departments, two alternative
procedures to invite patients to participate in the study
will be used. On the basis of team organization and
availability of time, the physician of the medical unit will
choose to recruit patients with either the ‘face-to-face
procedure’ or the ‘post procedure’. In the ‘face-to-face
procedure’, a member of the medical team will explain
the study briefly and invite the patient to participate. If
the patient agrees to participate, he/she will immediately
receive a study package with the informed consent form,
a ‘what to do’-scheme, the first questionnaire and a
stamped and addressed envelope to return the question-
naire. In the ‘post procedure’, eligible patients will be
sent an identical study package by post, containing a
short letter explaining the study, the informed consent
form, a ‘what to do’-scheme, the first questionnaire and
a stamped and addressed envelope to return the ques-
tionnaire. One week later participants have to fill in the
second questionnaire, containing the CARES for test-
retest reliability, and send it back in another stamped
and addressed envelope provided. If the questionnaire is
not sent back, the participants recruited via the ‘face-to-
face procedures will be contacted by a team member
and asked if they still want to participate and asked to
return a completed questionnaire. Participants invited
through post-procedure will be sent a reminder and sec-
ond questionnaire package after 1 month. This study
procedure is visualized in Fig. 1.
Participants will be contacted by phone or by e-mail
when returned questionnaires have a large number of
missing responses or if the second questionnaire is not
received in the expected timespan. Ethical standards
limit the number of participant contacts, there is a max-
imum of two attempts to contact a participant.
Questionnaires
Data collected with the first questionnaire includes socio-
demographic characteristics, medical characteristics, the
CARES and several concurrent instruments measuring
the same concepts as the CARES or its subscales. These
seven independent, but complementary, instruments are
all considered to be international ‘gold standards’ or are
frequently used instruments. These instruments were se-
lected as they represent domains similar to the summary
scales and global score of the CARES. All of them have
been previously used in Belgian research. The concurrent
validity of the original CARES was evaluated in compari-
son with the SCL-90, DAS and the KPS [34]. However,
these instruments do not match the content of the CARES
as completely as the set of concurrent measures in current
study does. The concept equivalence and expected correl-
ation with the CARES, to evaluate concurrent validity, is
shown in Table 5.
CARES [31–37]
The original CARES contains 139 items; however, not all
139 items apply to all patients and therefore patients
complete a minimum of 93 items or a maximum of 132
items. Patients can rate each item, formulated as prob-
lem statement, on a 5-point Likert scale with zero repre-
senting “not at all” (no problem) and four representing
“very much” (severe problem). The clinical form of the
instrument that will be used in this study allows a pa-
tient to indicate which problems they believe require
help, ticking ‘yes’ or ‘no’ on the question ‘Do you want
help?’. Scores for the five summary scales can be com-
puted as well as a CARES global score and an average
severity score.
Karnofsky Performance status Scale (KPS) [48, 54, 55]
The KPS is an 11-point scale to judge the physical and
daily functioning of a patient and ranges from 0 (com-
pletely dependent, not able to care for oneself) to 100
(fully active, not dependent and capable of normal activity
without limitations). This measure is currently used
worldwide in research and practice and has been adminis-
tered for many years. The KPS has got good psychometric
properties (interrater reliability: r = .97; concurrent valid-
ity: p < .001; predictive validity: r = .30).
Table 4 Inclusion and exclusion criteria for eligible patients
Inclusion criteria Exclusion criteria
▪ Male and female cancer patients
▪ Primary stage I, II and III diagnosis a
▪ At different stages of the care process:
recently diagnosed, currently undergoing
treatment, and post-treatment in follow-up care.
▪ All types of cancer
▪ Aged between 25 and 60 years b
▪ Having had or having premorbid neurological
problems or cognitive dysfunctions
▪ The lack of proficiency in Flemish-Dutch
a This criteria serves to exclude palliative patients, since we aim to include participants that have an perspective on rehabilitation
b We believe the social context, role fulfillment, obligations and expectations differ between adolescents, adults and elderly resulting in other psychosocial
concerns. To recruit adult cancer patients we chose the age range of 25–60 years
c This makes a person unsuitable for participation in questionnaire research
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The Hospital Anxiety and Depression Scale (HADS) [56–58]
The HADS was developed to identify symptoms of anx-
iety and depression in medically ill patients, and is used
extensively in cancer patients and had excellent psycho-
metric qualities. The questionnaire contains 14 items
with four possible answers with scores ranging from 0 to
3. Higher scores on the two subscales (each consisting of
seven items) indicate a higher level of anxiety or depres-
sion and the total score of the HADS (score-ranges from
0 to 42) can be used as a global measure of psychological
distress. The HADS has got good psychometric proper-
ties (internal consistency: α = .67–.93; PCA: two factor
solution; concurrent validity: r = .49–.83; subscale inter-
correlations: r = .40–.74).
The Social Support List – Interactions and Discrepancies
(SSL-I and –D) [59–61]
The SSL is a questionnaire with 75 items, 41 on experi-
enced social interaction and 34 on experienced social dis-
crepancies. In the first part of the questionnaire
participants indicate how frequently certain social interac-
tions occur on a 4-point Likert scale from 1 (‘seldom or
never’) to 4 (‘very often’), with higher scores representing
higher levels of social support. A second part of the SLL
indicates the social discrepancies participants experience
ranging from 1 (‘I would like it to happen more often’) to
4 (‘it happens too often’). Higher scores on the SSL-D in-
dicate a greater lack of social support. The psychometric
properties of the SSL are positively evaluated (internal
consistency: α = .53–.93, test-retest reliability: r = .62–.85).
The Maudsley Marital Questionnaire (MMQ) [62–65]
The MMQ contains three scales exploring Marital (10
items), Sexual (five items) and General Life (five items)
adjustment. The respondent is asked to indicate an an-
swer from a series of possible answers, on a scale ran-
ging from 0 to 8. The wording of response categories
differ for each item depending on nature of the question.
The MMQ has good psychometric properties (internal
consistency: α = ..66–.90; PCA: three factor solution;
subscale inter-correlations: r = .33–.60).
The European Organisation of Research and Treatment for
Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-
C30) [66]
The EORTC QLQ-C30 is an internationally validated
and widely used cancer-targeted QOL instrument, in-
corporating five functional scales (physical, role, cogni-
tive, emotional and social) and three symptom scales
(fatigue, pain and nausea, and vomiting). Items are
Fig. 1 Study procedure
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answered on a 4-point Likert scale from 1 (‘not at all’) to
4 (‘very much’). The last two items on global health and
QOL have 8-point answering scales ranging from 1
(‘very poor’) to 7 (‘excellent’). The EORTC QLQ -C30 is
subject of a many validation studies worldwide, generally
concluding the questionnaire is a QOL instrument with
good psychometric properties relevant to different
cancer-patient populations (internal consistency: α
= .52–.92; test-retest reliability: r = .72–.84; scale inter-
correlations: r = -.69–.85; responsive to change of health
status).
The Distress Thermometer (DT) together with a Problem List
(PL) [67–69]
Patients are asked to rate their overall distress on a vis-
ual analogue scale (presented as a thermometer) from 0
(‘no distress’) to 10 (‘extreme distress’). The DT is ac-
companied by the PL, which includes 35 items that ad-
dress five life domains (practical, family/social,
emotional, spiritual, and physical problems). Participants
indicate if the topics of the items poses problems for
them. At the end of the survey people are asked if they
want to talk to a professional about their problems. The
DT is frequently used in clinical practice and research
all over the globe, in combination with the PL. This has
proved to have good internal consistency (α = .80–.90).
Care Needs questionnaire [70]
The Care Needs questionnaire was developed to assess
the care needs of cancer survivors regarding relevant
themes during reintegration: physical functioning, psy-
chological functioning, self and body image, sexuality,
relationship with partner, relationship with others and
work and social security related aspects. For each theme,
participants are asked whether they wish to receive in-
formation or support, in what way, when they prefer to
receive information and support, and to what extent this
need already has been met. Each of the questions are
answered on 3- and 4-point Likert scales with different
wording.
The second questionnaire contains a second CARES
survey and specific supplementary questions to get data
on participants’ experiences with the CARES. This sec-
ond study component will be completed to assess test-
retest and a patient-acceptability of the measure. Table 6
gives a detailed summary on the composition of both
questionnaires and the measured concepts.
Ethical considerations
All local ethical committees of the participating hospitals
(Ethical Review Commission Jessaziekenhuis; Committee
Medical Ethics Ziekenhuis Oost-Limburg; Ethical Com-
mittee AZ Vesalius; Ethical Committee Mariaziekenhuis
Noord-Limburg) and the university (Medical Ethical
Committee Hasselt University) reviewed all study mate-
rials including: the recruitment materials and procedure,
informed consent form, the questionnaires and the over-
all study protocol. The leading ethical committee (ERC
Jessaziekenhuis) coordinated the process, collected feed-
back and granted approval on 26th of February 2014
(BE24320149544). The leading ethical committee also
reviewed and approved study protocol amendments.
Data analysis
The Statistical Package for Social Sciences (SPSS; Chi-
cago, IL) version 22.0 will be used for statistical analyses
of the quantitative data. A range of analyses are required
to report the reliability and validity of the translated
CARES version.
Reliability
The reliability of the CARES will be evaluated by com-
puting the internal consistency of summary scales, with
the aim to find a Cohen’s Alpha of at least .70 [71, 72].
Test-retest reliability will be investigated by computing
the intra-class correlations between the summary scale
Table 5 Expected correlations of concurrent measures with CARES summary scales and global score






CARES Global score EORTC-QLQ -C30 -
CARES Global score DT +
CARES Needs Care Needs Questionnaire E. Pauwels +
a ‘-‘= negative correlation, ‘+’ = positive correlation
Abbreviations CARES Cancer Rehabilitation Evaluation System, KPS Karnofsky Performance status Scale, HADS Hospital Anxiety and Depression Scale, SSL-I Social
Support List – Interactions, SSL-D Social Support List – Discrepancies, MMQ-M Maudsley Marital Questionnaire – Marital, MMQ-S Maudsley Marital Questionnaire –
Sexual, EORTC-QLQ -C30 European Organisation of Research and Treatment for Cancer Quality of Life Questionnaire Core 30, DT Distress Thermometer
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scores and total-CARES scores of the first and second
CARES administration, requiring a correlation ≥ .70
[71, 73].
Construct validity
The five factor structure as found in previous CARES-
research will be examined with principal component
analysis to evaluate construct validity. Following previ-
ous validation techniques applied in the original CARES
development process, items and subscales with a factor
loading higher as .30 are seen as loading on a factor [34,
35]. Confirmatory factor analysis will not be applied
since sample size will be limited. As well inter-
correlations of summary scales and the CARES Total
will be explored. Moderate correlations between the sub-
scales (r = |.30|-|.70|) and moderate to high correlations
with the CARES Total (r ≥ .30) would support construct
validity, since this would indicate that the subscales in-
deed measure distinct, but related concepts that contrib-
ute to the larger concept of QOL.
Concurrent validity
Spearmans rank correlations will be computed to evalu-
ate concurrent validity of the CARES global score and
the summary scales with the seven concurrent instru-
ments (Table 5). Correlations will be judged low, moder-
ate and high, when their absolute values are respectively
< .30, from .30 to .50 and ≥ .50 [74].
If the psychometric qualities do not show as expected,
these will be studied in more detail with qualitative
research data on CARES content and feasibility to
search for explanations.
Discussion
To achieve good quality care it is important to provide it
as efficiently as possible, and adapted to the individual
needs of every patient. A stepped care approach accord-
ing to patients’ level of need could serve to tailor care ef-
ficiently and appropriately, however this necessitates
reliable and valid screening and assessment tools to sup-
port clinicians in the identification of psychosocial con-
cerns and care needs of their patients. The current
English CARES is such an instrument. This paper de-
scribes a comprehensive protocol for translating and val-
idating a Flemish CARES version. This addresses a
critical gap in current clinical screening, and adds a tool
to assess and improve the delivery of patient-centered
care.
Unique in this study is the use of a wide range of com-
parative instruments to examine the concurrent validity
of the CARES. Many other validation studies use only a
few dimensions, not reflecting the whole concept of the
specific instrument [28, 29, 75]. In contrast, this study
will include an instrument to examine concurrent valid-
ity almost for each summary scale and the CARES global
score. While our study is set up to examine the psycho-
metric quality of the Flemish CARES, an additional ad-
vantage is that the use of several concurrent instruments
will provide us with a wealth of data. The use of the
KPS, HADS, SSL, MMQ, EORTC QLQ-C30, DT, PL
Table 6 Composition of questionnaires for quantitative data collection
Questionnaires Instrument Data collected
Questionnaire 1
T0Baseline Self-administered questions
on socio-demographic and medical aspects
Age, sex, marital status, children, education,
employment status, household income, social
surrounding, involved care providers, diagnosis,
date of diagnosis, treatment(s), start and end
dates of treatments.
CARES Quality of life and rehabilitation needs
KPS Physical and daily functioning
HADS Symptoms of anxiety and depression
SSL Social support
MMQ Marital and sexual life adjustment
EORTC-QOL-C30 Quality of life
DT + PL Distress and problems




T1After 1 week CARES Quality of life and rehabilitation needs
Self-administered questions Relevance of CARES-topics, timespan filling in, mode preference,…
Abbreviations CARES Cancer Rehabilitation Evaluation System, KPS Karnofsky Performance status Scale, HADS Hospital Anxiety and Depression Scale, SSL Social
Support List, MMQ Maudsley Marital Questionnaire, EORTC-QLQ -C30 European Organisation of Research and Treatment for Cancer Quality of Life Questionnaire
Core 30, DT Distress Thermometer, PL Problem List
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and the Care needs questionnaire of Pauwels et. al. pro-
vides data on psychological, social, marital and sexual
wellbeing, QOL, distress and care needs of patients
treated for cancer. These can be used to explore poten-
tial relationships between mutual care-domains and with
socio-demographic and medical characteristics. The re-
cruitment for this study has begun (March 2014) and
will continue until the end of 2014 or until the desired
sample size is reached.
As in all studies, this study has some limitations.
Firstly, the completeness of the CARES content to assess
QOL and supportive care needs should be considered.
In comparison to other psychometric positively evalu-
ated needs assessment tools for cancer patients, like the
Supportive Care Needs Survey (SCNS) [76], the CARES
does not include items on spiritual and existential well-
being [29]. However, on other domains of well-being, we
can judge in favor of the CARES content. The content
of the CARES matches with our thoughts about the bio-
psychosocial impact of cancer on patients’ lives and pos-
sibly resulting care needs. Furthermore, the content val-
idity, completeness and feasibility of the CARES for
Flemish cancer patients will be explored in the qualita-
tive part of the larger study combining qualitative and
quantitative methods. If the results of the study de-
scribed in this research protocol result in a negative
evaluation of the CARES’ psychometric properties, or it
appears from the focus group discussions that there are
deficits in the CARES content, formulation of items, or
feasibility, adjustments for an improved Flemish version
will be made. We plan to use this ‘final’ Flemish version
in a pilot study where it will support the routine assess-
ment and management of patients’ psychosocial con-
cerns and needs in a clinical pathway with medical and
psychosocial components. In the future, the instrument
will also be made available for use in clinical practice.
Secondly, the use of two procedures to invite patients to
participate in the study can introduce bias. An invitation
to participate in research from a member of the medical
team or by post could result in different response rates in
both subgroups. This is a demanding study for patients
and therefore also for professionals to convince patients to
participate. Hence, some flexibility in the process of pa-
tient recruitment is needed. Some departments prefer a
personal approach and want to invite their patients for the
research personally, while others do not find the time in
the clinical appointment to do this. Both procedures have
been previously used in other validation research [66, 75,
77–80]. To assess any recruitment or consent bias, we will
compare the data from the group of patients invited to
participate in the hospital to the group invited by post.
Thirdly, the questionnaire package composed with the
CARES and several concurrent instruments asks for a
time-investment of approximately an hour. This could
present a burden to participants, resulting in discontinu-
ation of participation. However, preliminary study results
report approximately 58 % of the questionnaires distrib-
uted were returned completed. Eighty-four percent of
the 153 participants who returned the first questionnaire
also returned the second questionnaire completed.
Fourthly, the time between completing of the first and
the second CARES survey could pose some problems.
To examine test-retest reliability of an instrument the
time period between two completions should be short
enough to ensure that clinical change has not occurred,
though long enough to prevent recall. While 1 or 2 weeks
are recommended in literature [53], we ask participants
to fill out the second questionnaire 1 week after the first.
Preliminary results have shown some participants forget
to fill in the second questionnaire or do not do so in a
timely manner. They are reminded with a phone call by
the researcher when de second questionnaire is not re-
ceived in the recommended period of time. When data
collection is completed, the time span between the two
CARES-completions will be evaluated.
Fifthly, in earlier research the CARES was validated
and used as a research tool for participants with various
types of cancers, various cancer stages, at different
phases of the care process, and often without age restric-
tions [31–44]. Because of the strict inclusion criteria we
applied in our study, we have to state that the validation
evidence from this study will not apply to patients above
60 years of age, and those with metastatic disease or in
palliative care.”
Conclusions
In summary, this study protocol describes a unique and
thorough examination of the psychometric robustness of
a QOL and needs assessment tool. Internal consistency
of summary scales, test-retest reliability, content validity,
feasibility, construct validity and concurrent validity of
the Flemish CARES are explored. Likewise, the use of
several concurrent instruments will provide insight in
the QOL, physical, emotional, social, relational and sex-
ual functioning and well-being, distress and care needs
of the research population. We expect to find positive
results on the reliability and validity of the Flemish
CARES version. Comprehensive assessment with the
CARES throughout the care trajectory can contribute to
timely identification of cancer patients psychosocial con-
cerns and care needs to refer them to tailored care and
improve the quality of psychosocial cancer care.
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